Falkson C I, Falkson G, Falkson H C
Department of Medical Oncology, University of Pretoria, South Africa.
J Clin Oncol. 1991 Aug;9(8):1403-8. doi: 10.1200/JCO.1991.9.8.1403.
Sixty-four patients with histologically confirmed metastatic malignant melanoma were entered on a prospectively controlled randomized trial. Patients received dacarbazine (DTIC) alone or DTIC plus interferon (IFN) alfa-2b. Patients were reasonably balanced with respect to age, sex, performance status (PS), site of metastases, and number of metastatic sites. Objective response (complete plus partial remission [CR + PR]) was documented in six patients on DTIC and in 16 patients on DTIC plus IFN alfa-2b. Median time to treatment failure (TTF) and median survival are significantly better on the combination arm, with some long-term CRs observed. More toxicity was encountered in the combination arm, which was acceptable except in three patients where treatment was discontinued because of IFN toxicity.
64例经组织学确诊为转移性恶性黑色素瘤的患者进入一项前瞻性对照随机试验。患者单独接受达卡巴嗪（DTIC）或DTIC加干扰素（IFN）α-2b治疗。患者在年龄、性别、体能状态（PS）、转移部位和转移灶数量方面基本均衡。单独使用DTIC治疗的6例患者和使用DTIC加IFNα-2b治疗的16例患者出现了客观缓解（完全缓解加部分缓解[CR + PR]）。联合治疗组的中位治疗失败时间（TTF）和中位生存期明显更好，观察到一些长期CR病例。联合治疗组出现了更多的毒性反应，除3例因IFN毒性而停药的患者外，其余毒性反应均可接受。
